Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Saved in:
| Title: | Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters. |
|---|---|
| Authors: | Zaeck LM; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Tan NH; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., Rietdijk WJR; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., Geers D; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Sablerolles RSG; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., Bogers S; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., van Dijk LLA; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Gommers L; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., van Leeuwen LPM; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Rugebregt S; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Goorhuis A; Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, the Netherlands.; Infection and Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands., Postma DF; Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the Netherlands., Visser LG; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands., Dalm VASH; Department of Internal Medicine, Division of Allergy and Clinical Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.; Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands., Lafeber M; Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands., Kootstra NA; Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Institute for Immunology and Infectious Diseases, University of Amsterdam, Amsterdam, the Netherlands., Huckriede ALW; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Haagmans BL; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., van Baarle D; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., Koopmans MPG; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., van der Kuy PHM; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., GeurtsvanKessel CH; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands. c.geurtsvankessel@erasmusmc.nl., de Vries RD; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands. |
| Corporate Authors: | SWITCH-ON Research Group |
| Source: | Nature communications [Nat Commun] 2024 May 18; Vol. 15 (1), pp. 4224. Date of Electronic Publication: 2024 May 18. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-48414-x |
